-MPC should be closely followed because of the risk for multifocality/recurrence.
Myopericytoma (MPC) describes rare, nodular tumors characterized by a radial and multilayered perivascular growth of ovoid and spindled-shaped cells with mesenchymal stem-cell-like features, often with associated blood vessels arranged in an irregular, "staghorn" pattern (1) (2) (3) . Most MPCs are benign (2) , but some are malignant with metastatic potential and poor survival (4, 5) .
MPCs arise over a wide age range, primarily affecting subcutaneous tissues of the distal extremities (2) , and lesions occasionally present with skin ulceration, pain or tenderness; additionally, symptomatic MPCs arise in the proximal extremities, head region and internal organs (1) . Most MPC are treated surgically, and complete excision should prevent recurrent/persistent disease, although negative surgical margins are difficult to achieve outside of the extremities (2) .
Biomarkers and oncogenic events driving MPC development are not well understood. In this study, we performed a comprehensive genomic and functional validation of associated MPC biomarkers with clinical implications. We have applied a high-throughput genotyping assay on 29 MPCs from available, formalin-fixed paraffin-embedded (FFPE), discarded/unidentified samples, using an Institutional Review Board-approved protocol (Beth Israel Deaconess Medical Center, Boston, MA) to unravel oncogenic events driving pathogenesis (Supplementary Methods and  Supplementary Table 1 , available online). The patient with thyroid MPC provided written informed consent for genetic analysis. For all other patients, we used discarded/ unidentified tissue specimens and consent for genotyping test. Disease stage was assessed by radiologic imaging. We also used and immunohistochemistry, primary cell cultures, dynamic functional assays, shRNA, and developed an MPC-patient-derived xenograft (PDX) mouse model (for detailed methods, please see the Supplementary Methods, available online). All animal work was done in accordance with federal, local, and institutional guidelines at the Beth Israel Deaconess Medical Center (Boston, MA), and all experiments were performed with four-month-old Crl:NU(NCr)-Foxn1nu female, athymic, immunodeficient, nude mice (strain code: 490) (Charles River, Wilmington, MA) (n = 5 per group).
Statistical analysis was carried out using GraphPad Prism 6 software (version Prism 6, GraphPad Software Inc., San Diego, CA). Mann-Whitney test was used to analyze the statistical significance of differences between two groups. For categorical data, Fisher's exact test was used. All reported P values were two sided. Data are reported as the averaged value, and error bars represent the standard deviation of the average for each group in duplicate or triplicate. Results with P values below .05 were considered statistically significant.
We developed the first translational model to date of multifocal and infiltrative thyroid MPC (Figure 1 ; Supplementary  Figures 1 and 2 , available online). The the Ki67 proliferation index (arrows highlight nuclear staining) is low in the MPC cells. C2) The MPC cells are clustered with a fascicular growth pattern around the vessels (clear, slit-like spaces, V) with intralesional, thin-walled branching vessels of small caliber, highlighted by CD31 (C2). C3-C4) MPC cells show cytoplasmic to membranous staining with antibodies against α-smooth muscle actin (αSMA) and platelet-derived growth factor receptor beta (PDGFRB). C5) MPC cells also show positivity (punctate) for NG2 (chondroitin sulfate proteoglycan 4) but are negative for desmin (C6). C7) Trichrome staining highlights the abundant amount of collagen deposition (blue staining, asterisk) surrounding the MPC (purple staining) or the intratumoral deposition of collagen (arrows). D1-D2) DNA genotyping analysis by mass spectrometry (MS) traces of formalin-fixed paraffin embedded thyroid (n = 1) (D1) and (D2) skin (eg, leg) (n = 28) MPC tissue samples reveals a heterozygous BRAF WT/V600E allele (long arrows) (A > T). The intensity of the signal vs mass of the analyte is plotted in the background, while the inset shows the cluster plot with all samples analyzed in the run (intensity of the signals of the two alleles). The long arrow links the actual sample (circle in the inset) to the mass of the expected mutant V600E allele. Color coded by the software is automatic allele calls. Cyan squares for heterozygous samples, orange triangles for homozygous. Ambiguous calls are identified by a red dot. Allele frequencies deviating from the expected values are assigned ambiguous or homozygous calls by the software. (6) Figure 1A5;Supplementary Figure 1 , G-J, available online). Furthermore, our analysis of X-chromosome inactivation and methylation profile from the female patient with thyroid BRAF W/V600E -MPC ( Figure 1D1 and Figure 2 , A1 and A2) revealed that this tumor was monoclonal compared to the adjacent, uninvolved thyroid tissue ( Figure 2A3 ) (7) .
To provide a translational application for our study, we established early and late passages of primary cells cultured in vitro from human thyroid BRAF WT/V600E -MPC. These cells also harbored BRAF WT/V600E and expressed pericyte lineage-specific differentiation biomarkers ( Figure 2A1) -MPC cells as compared with controls ( Figure 2C Figure 3A -MPC cell viability ( Figure 2G ; Supplementary Figure 5 , available online) and vascular density/angiogenesis (3.6-fold, P = .002) (Supplementary Figure 5 , available online) without any obvious toxicity. Subsequently, we found that COL1A1 (5-fold, P = .007), PDGFRB (1.3-fold increase, P = .02), integrin-β1 (ITGβ1) (1.7-fold increase, P = .02), ID2 (DNA-binding protein inhibitor) (6.5-fold increase, P = .002), and the long intergenic non-coding RNA (LincRNA) ID2 (2.8-fold increase, P = .02) were statistically significantly (with moderate or high copy number) BRAF Figure 2E ) were also statistically significantly reduced by vemurafenib treatment compared with BRAF WT -pericytes. MPCs continue to be under recognized, resulting in inappropriate treatment and patient anxiety (12) . Benign MPCs are generally indolent tumors (1); however, when they involve internal organs, they may be locally aggressive, with recurrent/persistent disease because of difficulty of complete excision. We discovered that BRAF V600E is a distinct genetic alteration seen in benign MPCs, often multifocal and infiltrative. Patients with multifocal MPCs present a treatment dilemma, often requiring multiple surgeries for lesions that may be quite painful, even if not malignant. BRAF V600E is a prognostic biomarker of tumor recurrence and aggressiveness (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) and also facilitates tumorigenesis (25) (26) (27) (28) (29) . BRAF
WT/V600E
-induced MPC cell adhesion, migration, and angiogenesis associated with upregulation of molecules (eg, COL1A1, PDGFRB, ID2) (30) (31) (32) (33) Figure 6 , available online), which ultimately may lead to MPC aggressiveness. High doses of vemurafenib therapy were effective to inhibit BRAF V600E -MPC cell viability and angiogenesis, suggesting that this therapy blocked BRAF V600E -dependent pro-migratory pathways and so diminished pro-angiogenic capabilities of MPC cells.
Please see the Supplementary Results (available online) for additional findings that may be of interest.
Collectively, using anti-BRAF V600E therapy as a surgical adjuvant may provide a novel advancement in the therapeutic strategy and treatment of locally aggressive multifocal BRAF V600E -positive MPCs or possibly serve as a therapeutic alternative for cases in which surgical options are limited by location and extent of disease, or in medically poor surgical candidates.
Our study is limited by sample size (29 available MPCs), precluding optimal evaluation of MPC pathological features with/ without BRAF V600E . However, our results were substantiated by our integrated in vitro and in vivo approaches. It is also possible that MPC heterogeneity reduced the sensitivity for detection of the BRAF V600E mutation in some cases; therefore, we cannot exclude the possibility that the percentage of BRAF V600E -positive MPC cases is higher.
In conclusion, our results demonstrate a subset of MPC harbor BRAF V600E that drives tumor development. We report the first MPC arising in the thyroid. Anti-BRAF V600E therapy effectively suppresses viability in the only currently available MPC short-term cell culture that harbors the BRAF V600E mutation. BRAF V600E plays a role in the MPC microenvironment (Supplementary Figure 6 , available online) and might ultimately lead to aggressive behavior. Finally, we report a multiplex panel of diagnostic markers for MPCs in the run (intensity of the signals of the two alleles). The long arrow links the actual sample (circle in the inset) to the mass of the expected mutant V600E allele. Color coded by the software is automatic allele calls. Cyan squares for heterozygous samples, orange triangles for homozygous. Ambiguous calls are identified by a red dot. Allele frequencies deviating from the expected values are assigned ambiguous or homozygous calls by the software. These findings were validated by two independent experiments. A3) Methylation-sensitive PCR analysis of the X-chromosome locus was assessed on DNA isolated from manually dissected female thyroid MPC (n = 1) or non-malignant adjacent thyroid tissue (n = 1) formalin fixed paraffin embedded specimen. Screenshot of electropherogram displaying discordant patterns of X-chromosome inactivation (arrowheads) in the thyroid MPC vs the benign thyroid tissue. For each sample, the corresponding plot is a quantitative representation of the size and amount of fluorescent PCR products amplified from undigested DNA or digested DNA with the methylation-sensitive enzyme HpaII when analyzed on an automated DNA sequencer. The peaks indicate the estimated allele size (in base pairs) that is the corresponding peak height (amount of PCR product), as quantified by DNA Genotyper software. These findings were validated by triplicate sample assays. B) Thyroid MPC cells with heterozygous BRAF WT/V600E or normal pericytes with BRAF Wild Type(WT) were treated with the indicated concentrations of vemurafenib for 48 hours, and viability was determined using the Cell Titer-Glo ATP-based luminescence assay, with Dimethyl sulfoxide, control (DMSO)-treated cells as the control. Cell growth curves were determined following two to three days of treatment with DMSO or vemurafenib. Arrows highlight change of cell shape in MPC cells vs control. All scale bars are =10 µ (MPC cells images) and 50 µ (pericytes images). These data represent the average ± standard deviation (error bars) of eight independent replicate measurements (*P < .05, **P < .01, ***P < .001, Mann-Whitney test, two-sided). C) A parallel plate similar to (B) was set up and corresponding phospho(p)ERK1/2 and pMEK1/2 protein levels measured from BRAF images were captured by optical microscopy. GFP (green fluorescent protein) and merge images were captured on a different microscopy field by confocal microscopy analysis: HMVECs alone are stained with ICAM-1 (human intercellular adhesion molecule) (green); merge= GFP-tagged MPC cells or Alexa Fluo 488-conjugated CD90 (green)-tagged pericytes, and Alexa Fluo 594-conjugated actin (red)-tagged HMVECs. These data represent the average ± standard deviation (error bars) of six independent replicate measurements (**P = .002, Mann-Whitney test, two-sided). E) Cell migration assays within five hours in human primary thyroid MPC cells with BRAF WT/V600E or in pericytes with BRAF WT in the presence of vehicle (control) or vemurafenib treatment. These data represent the average ± standard deviation (error bars) of six independent replicate measurements (**P = .002, Mann-Whitney test, two-sided). F) Quantitation of mRNA expression levels (copy number) by multi-gene transcriptional real-time reverse transcriptase PCR (RT-PCR) analysis of genes fundamental for extracellular matrix (ECM) remodeling and angiogenesis in human primary thyroid MPC cells with BRAF WT/V600E or in pericytes with BRAF WT in the presence of vehicle (control) or vemurafenib treatment for 24 hours (0.2% serum cell growth medium). Gene expression was classified as "low copy number" if it was below 1 mRNA copy/10 6 18S copies, "moderate copy number" if it was between 1 and 15 mRNA copies/10 6 18S copies, and "high copy number" if it was greater than 15 mRNA copies/10 6 18S copies. These data represent the average ± standard deviation (error bars) of four to six independent replicate measurements (*P < .05; **P < .01: ***P < .001, Mann-Whitney test, two-sided). Genes showing difference in values of comparisons (P values <.05) were considered differentially expressed and statistically significant. G) A patient-derived xenograft (PDX) mouse model of BRAF WT/V600E -human primary thyroid MPC cells engineered to express GFP (green fluorescent protein, scale bar=100 µ) injected in the subcutaneous compartment of the left ear of nude mice (n = 10) to visually follow perivascular growth of MPC cells over time in vivo. Mice were treated starting four days after BRAF
-MPC cells implantation (defined 'baseline') with vemurafenib (100 mg/kg twice daily by oral gavage) (n = 5) or vehicle (n = 5) for two consecutive weeks. MPC cell viability was determined by the CS5.1 histogram software calculating the absolute number of pixels in the GFP-positive areas (arrows) of the left ear divided by the total number of pixels (247,545) in the highlighted selection area. These data represent the average ± standard deviation of two independent experiments (control-treated mice vs vemurafenib-treated mice, P = .007, Mann-Whitney test).
(eg, PDGFRB, NG2, αSMA, peritumoralfibronectin, vimentin, CollagenIA1).
We propose that genetic testing for the BRAF
-mutation is part of the pathologic evaluation for multifocal and infiltrative MPCs, and patients with BRAF WT/V600E -positive MPCs should be periodically reevaluated for recurrence, especially with available targeted drug therapies.
